Neoplasms

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Rare Diseases

Carcinoma

Carcinoma, Transitional Cell

Urinary Bladder Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Transitional Cell Carcinoma

Antineoplastic Agents

All Drugs and Chemicals

Atezolizumab

Mitogens

Antibodies

Antibodies, Monoclonal

Immunoglobulins

Immune Checkpoint Inhibitors

Antineoplastic Agents, Immunological

Immunologic Factors

Patients with urothelial cancer were treated with derazantinib 300 mg once daily

Patients with any solid tumors were treated with derazantinib 200 mg once daily in combination with atezolizumab 1200 mg given every 3 weeks as intravenous (IV) infusion

Patients with any solid tumors were treated with derazantinib 300 mg once daily in combination with atezolizumab 1200 mg given every 3 weeks as IV infusion

Patients with urothelial cancer were treated with derazantinib 200 mg twice daily in combination with atezolizumab 1200 mg given every 3 weeks as IV infusion

Patients with FGFR inhibitor resistant urothelial cancer were treated with derazantinib 300 mg once daily

Patients with urothelial cancer were treated with derazantinib 300 mg once daily in combination with atezolizumab 1200 mg given every 3 weeks as IV infusion

Patients with urothelial cancer were treated with derazantinib 200 mg twice daily

Derazantinib was administered orally at a dose of 300 mg once daily

Derazantinib 300 mg once daily monotherapy

Derazantinib was administered orally at a dose of 200 mg once daily in combination with atezolizumab 1200 mg every 3 weeks

Derazantinib 200 mg once daily + atezolizumab 1200 mg

Derazantinib was administered orally at a dose of 300 mg once daily in combination with atezolizumab 1200 mg every 3 weeks

Derazantinib 300 mg once daily+ atezolizumab 1200 mg

Derazantinib was administered orally at a dose of 200 mg twice daily in combination with atezolizumab 1200 mg every 3 weeks

Derazantinib 200 mg twice daily + atezolizumab 1200 mg

Derazantinib 300 mg once daily monotherapy (QD)

Derazantinib 300 mg once daily + atezolizumab 1200 mg

Derazantinib was administered orally at a dose of 200 mg twice daily

Derazantinib 200 mg twice daily monotherapy

Manuel Häckl, MD

The purpose of this study was to evaluate efficacy of derazantinib monotherapy or derazantinib-atezolizumab in combination in patients with advanced urothelial cancer harboring fibroblast growth factor receptor (FGFR) genetic aberrations (GA) of various clinical stages of disease progression and prior treatments.

The study comprised five open-label substudies (1-5) in patients with advanced urothelial cancer harboring FGFR GA (with the exception of substudy 2 which did not require a FGFR GA) who were treated by derazantinib monotherapy or derazantinib in combination with atezolizumab. The study enrolled patients with cisplatin-ineligible status, or patients whose disease progressed after either first-line treatment or prior treatment with FGFR inhibitors.

Derazantinib and Atezolizumab in Patients With Urothelial Cancer

An Open-label Multi-cohort Phase 1b/2 Study of Derazantinib and Atezolizumab in Patients With Urothelial Cancer Expressing Activating Molecular FGFR Aberrations

ORR was defined as the proportion of patients who achieved a confirmed clinical response (CR) or partial response (PR) by blinded investigator central review (BICR) using the internationally recognized criteria for the radiological assessment in tumor response of solid tumors (RECIST) Version 1.1

The RP2D was determined by a joint decision taken by the Independent Data Monitoring Committee (IDMC), Investigators, and the Sponsor in reviewing the aggregate of DLT and AE data, and considering efficacy data

In Substudy 2, the primary endpoint was the number of patients with DLTs. A DLT was defined as a clinically-significant adverse event (AE) or abnormal laboratory value assessed as unrelated to disease progression, intercurrent illness, or concomitant medications. Any DLT had to be a toxicity considered at least possibly related to derazantinib or the combination of derazantinib and atezolizumab

DCR was defined as the proportion of patients who achieved a confirmed clinical response (CR), partial response (PR) or stable disease (SD) by BICR using the internationally recognized criteria in accordance with RECIST Version 1.1

DOR was calculated from the first date of documented tumor response (confirmed CR or PR) to the date of disease progression as assessed by BICR or death per RECIST 1.1

PFS was calculated as the time from cohort assignment until disease progression as assessed by BICR, or death from any cause, whichever came first

OS was calculated from the date of cohort assignment until death from any cause

Common Terminology Criteria for Adverse Events (CTCAE) displayed by increasing severity grades 3 to 5 (CTCAE grade 3/4/5 )

Basilea Pharmaceutica

Patients with urothelial cancer were treated with derazantinib 300 mg once daily

Derazantinib 300 mg once daily monotherapy: Derazantinib was administered orally at a dose of 300 mg once daily

Substudy 1: Derazantinib 300 mg Once Daily

Patients with solid tumors were treated with derazantinib 200 mg once daily in combination with atezolizumab 1200 mg given every 3 weeks as IV infusion

Derazantinib 200 mg once daily + atezolizumab 1200 mg: Derazantinib was administered orally at a dose of 200 mg once daily in combination with atezolizumab 1200 mg every 3 weeks

Substudy 2 (Dose-Level 1): Derazantinib 200 mg Once Daily + Atezolizumab 1200 mg

Patients with solid tumors were treated with derazantinib 300 mg once daily in combination with atezolizumab 1200 mg given every 3 weeks as IV infusion

Derazantinib 300 mg once daily + atezolizumab 1200 mg: Derazantinib was administered orally at a dose of 300 mg once daily in combination with atezolizumab 1200 mg every 3 weeks

Substudy 2 (Dose-Level 2): Derazantinib 300 mg Once Daily + Atezolizumab 1200 mg

Patients with urothelial cancer were treated with derazantinib 200 mg twice daily in combination with atezolizumab 1200 mg given every 3 weeks as IV infusion

Derazantinib 200 mg twice daily + atezolizumab 1200 mg: Derazantinib was administered orally at a dose of 200 mg twice daily in combination with atezolizumab 1200 mg every 3 weeks

Substudy 3: Derazantinib 200 mg Twice Daily + Atezolizumab 1200 mg

Substudy 4 (Cohort 4a):Derazantinib 300 mg Once Daily

Patients with urothelial cancer were treated with derazantinib 300 mg once daily in combination with atezolizumab 1200 mg given every 3 weeks as IV infusion

Derazantinib 300 mg once daily + atezolizumab 1200 mg: Derazantinib was administered orally at a dose of 300 mg once daily in combination with atezolizumab 1200 mg every 3 weeks

Substudy 4 (Cohort 4b):Derazantinib 300 mg Once Daily + Atezolizumab 1200 mg

Patients with urothelial cancer were treated with derazantinib 200 mg twice daily

Derazantinib 200 mg twice daily monotherapy: Derazantinib was administered orally at a dose of 200 mg twice daily

Substudy 5: Derazantinib 200 mg Twice Daily

Patients with solid tumors were treated with derazantinib 200 mg once daily in combination with atezolizumab 1200 mg given every 3 weeks as IV infusion

Derazantinib 200 mg once daily+ atezolizumab 1200 mg: Derazantinib was administered orally at a dose of 200 mg once daily in combination with atezolizumab 1200 mg every 3 weeks

Substudy 2 (Dose-Level 1): Derazantinib 200 mg Once Daily+ Atezolizumab 1200 mg

Patients with solid tumors were treated with derazantinib 300 mg once daily in combination with atezolizumab 1200 mg given every 3 weeks as IV infusion

Derazantinib 300 mg once daily+ atezolizumab 1200 mg: Derazantinib was administered orally at a dose of 300 mg once daily in combination with atezolizumab 1200 mg every 3 weeks

Substudy 2 (Dose-Level 2): Derazantinib 300 mg Once Daily+ Atezolizumab 1200 mg

Total

Age, Continuous

Sex: Female, Male

Race (NIH/OMB)

Bladder

Renal pelvis

Ureter

Missing

Other site of primary tumor

Site of primary tumor at diagnosis

Scale 0

Scale 1

Scale 2

The ECOG PS scale indicates increasing levels of disability, with 0 indicating fully active; 1, restricted in strenuous activity; 2, restricted in work activity but ambulatory and capable of self-care

Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)

One treatment

Two treatments

Three or more treatments

No treatment

Number of previous anti-cancer treatments

Prior immune checkpoint inhibitor treatment

Treatment completed

Progressive disease

Toxicity

Other

Unknown

No previous therapy

Reason previous therapy ended

Study Director

Efficacy analyses were performed using the modified Intent-to-Treat (mITT) population: all patients who received at least one dose of derazantinib or atezolizumab, and had at least one post-baseline imaging assessment in accordance with RECIST 1.1, or documented clinical progression

Objective Response Rate (ORR) Based on RECIST 1.1 (Substudies 1,3,4 and 5)

Patients with solid tumors were treated with derazantinib 200 mg or 300 mg once daily in combination with atezolizumab 1200 mg given every 3 weeks as IV infusion

Substudy 2 Combined (Dose-Level 1 and 2): Derazantinib 200 or 300 Once Daily+ Atezolizumab 1200 mg

The safety/intent-to-treat (ITT) population consisted of all patients who received at least one dose of derazantinib or atezolizumab

Recommended Phase 2 Dose (RP2D) of Derazantinib-atezolizumab in Combination Based on DLT Criteria, Safety and Efficacy Data (Substudy 2)

The maximum tolerated dose (MTD)-determining population included all patients enrolled in the MTD Part of each dose level who met the following minimum criteria during the DLT period:

* received at least one dose of derazantinib and atezolizumab and has experienced a DLT;
* received ≥ 90% of the derazantinib and atezolizumab dose, respectively, in Cycle 1 and did not experience a DLT, have been observed for ≥ 21 days following the first dose, and have been evaluated for safety

Number of Patients With Dose-limiting Toxicities (DLTs) in Substudy 2

Disease Control Rate (DCR) Per RECIST 1.1 in All Substudies

Duration of Response (DOR) Per RECIST 1.1

Efficacy analyses were performed using the modified Intent-to-Treat (mITT) population: all patients who received at least one dose of derazantinib or atezolizumab, and had at least one post-baseline imaging assessment in accordance with RECIST 1.1, or documented clinical progression.

ORR Based on RECIST 1.1 (Substudy 2)

Progression-free Survival (PFS) by RECIST in All Substudies

Overall Survival (OS) in All Substudies

Number of Patients With at Least Grade 3 Adverse Events (AEs)

Patients with solid tumors were treated with derazantinib 200 mg once daily in combination with atezolizumab 1200 mg given every 3 weeks as intravenous (IV) infusion

Derazantinib 200 mg once daily + atezolizumab 1200 mg: Derazantinib was administered orally at a dose of 200 mg once daily in combination with atezolizumab 1200 mg every 3 weeks

Patients with urothelial cancer were treated with derazantinib 300 mg once daily in combination with atezolizumab 1200 mg given every 3 weeks as IV infusion

Derazantinib 300 mg once daily + atezolizumab 1200 mg: Derazantinib was administered orally at a dose o f 300 mg once daily in combination with atezolizumab 1200 mg every 3 weeks

Overall Study

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Urinary Bladder Diseases

Urologic Diseases

Male Urogenital Diseases

Cisplatin

Infigratinib

* Infigratinib daily dosage per protocol 3-week on/1-week off schedule. 4 weeks will constitute 1 cycle of therapy.
* Participants will receive 2 cycles (i.e. 8 weeks) and the treatment will be administered as an outpatient.
* After completion of therapy, patients will undergo a CT of the chest, abdomen and pelvis (within 2 weeks of the last dose of therapy) and then proceed to Radical cystectomy 2-4 weeks after the last dose of therapy.

Guru Sonpavde, MD

The aim of this research is to see whether using a drug that blocks a protein called FGFR (fibroblast growth factor receptor) prior to surgery is safe and effective in patients with bladder cancer that have mutations in FGFR3 or FGFR2 and who cannot receive chemotherapy with cisplatin prior to surgery

The name of the study drug involved in this study is:

- Infigratinib

This is a single-center (DF/HCC) prospective feasibility study to assess biomarker-directed neoadjuvant therapy in patients with cT2-T4aN0 MIBC who are candidates for radical cystectomy (RC) and ineligible for, or refuse, cisplatin-based neoadjuvant chemotherapy (NAC).

This research study involves using a drug that inhibits FGFR in patients with bladder cancer (that have mutations in FGFR) prior to surgery.

The name of the study drug involved in this study is:

- Infigratinib

The research study procedures include pre-screening for eligibility and study treatment including evaluations and follow up visits. This pre-screening is already done as clinical care. Study participants will receive study treatment for 2 months prior to surgery and will be followed for at least 1 year after undergoing surgery.

It is expected that about 12 people will take part in this research study.

This research study is a Phase I clinical trial, which tests the safety of an investigational drug (infigratinib) and also tries to define the appropriate dose of the investigational drug to use for further studies. "Investigational" means that the drug is being studied.

This research study is also a Feasibility Study, which is the first time investigators are examining this drug in patients with bladder cancer that has not spread to other organs. The U.S. Food and Drug Administration (FDA) has not approved infigratinib as a treatment for any disease.

Phase I BLASST-3 Trial

Biomarker-directed Neoadjuvant Therapy for Cisplatin-ineligible or Cisplatin-refusing Muscle-invasive Bladder Cancer: Phase I Bladder Cancer Signal Seeking Trial

The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Feasibility is defined as ≥ 70% of patients receiving at least 1 dose of study treatment followed by completion of radical cystectomy in the absence of DLT up to 4 weeks post-RC.

Dose-limiting toxicities (DLTs) will be graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 criteria). DLT will be defined as an adverse event (AE) or abnormal laboratory value deemed related to therapy with infigratinib, including those AEs and abnormal laboratory values that result in a failure to meet the criteria for re-treatment.

Pathologic response is defined as \<pT2N0 disease at the time of RC (e.g. pT0N0, pT1N0, pTaN0, or pTisN0)

Pathologic complete response (pCR) is defined as achievement of pT0N0 disease at RC.

Relapse-free survival (RFS) is defined as the duration of time from time of RC to time of documented disease relapse or recurrence after RC, or death from any cause. Patients who have received at least one cycle of therapy and have undergone RC will be considered evaluable for RFS.

Progression prior to RC will be defined as radiologic progression by RECIST 1.1 with development of radiologic T4b and/or N1/N2/N3 and/or or M1 disease (per RECIST 1.1) in scans obtained after commencement of neoadjuvant therapy and prior to RC

QED Therapeutics, Inc.

Guru P. Sonpavde

Sponsor Investigator

Skin and Connective Tissue Diseases

Breast Neoplasms

Evaluation of safety and efficacy in patients with metastatic breast cancer whose tumors contain mutations to PIK3CA and alterations FGFR 1-3.

Patients with solid tumors (except for colorectal cancer) whose tumors express mutations to PIK3CA.

Patients with solid tumors (except for colorectal cancer) whose tumomrs express mutations to PIK3CA and alterations to FGFR 1-3

To determine the MTD or RDE of the combination of BGJ398 with BYL719 in patients with advanced or metastastic solid tumors that express mutations to PIK3CA.

BGJ398 will be administered orally once daily for the first 21 days of each 28-day cycle.

BGJ398

BYL719 will be administered orally once daily on each day of the 28-day cycle.

BYL719

Novartis Pharmaceuticals

To study the safety and efficacy of the combination of BGJ398 with BYL719 in patients whose tumors express mutations to PIK3CA with or without alterations to FGFR 1-3.

This dose escalation/dose expansion study will evaluate the combination of orally administered BGJ398 in combination with orally administered BYL719. During the dose escalation part, the MTD of the combination will be determined in patients whose advanced or metastatic tumors express mutations to PIK3CA. Once the MTD has been determined, the expansion part will begin. Patients will be addd to one of three arms based on the disease type and genetic changes. Patients with metastatic colorectal cancer are not eligible for participation in the expansion part.

Phase 1b Trial of BGJ398/BYL719 in Solid Tumors

A Phase Ib, Open-label Study of Oral BGJ398 in Combination With Oral BYL719 in Adult Patients With Select Advanced Solid Tumors

The dose escalation part of the study will be guided by a well-established statistical method/model to estimate the maximum tolerated dose(s) and/or the recommended dose for expansion (RDE). Safety(incidence and nature of DLTs), pharmacokinetic and pharmacodynamic data will guide dose escalation decisioins.

This will be assessed by looking at the number of Adverse Events (AEs), serious AEs (SAEs) changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs), dose interruptions and reductions

Assessment of preliminary antitumor activity of the combination of BGJ398 with BYL719; Overall response rate = complete response + partial response

Assessment of preliminary antitumor activity of the combination of BGJ398 with BYL719

Plasma concentration versus time profiles. Plasma PK parameters will be used to characterize the PK profiles of the combination of BGJ398 with BYL719

Lenvatinib

Protein Kinase Inhibitors

Enzyme Inhibitors

The starting dose of lenvatinib will be 24 mg orally per day. The duration of one cycle is defined as 28 days (4 weeks). Subjects will be treated for 2 cycles (8 weeks) and then restaged. Subjects will continue study drug until progression or unacceptable toxicity occurs.

Lenvatinib is administered orally at a starting dose of 24 mg per day. Lenvatinib is administered in cycles of 28 days.

Teresa Helsten, MD

This is a two center, open label, non-randomized Phase II study of lenvatinib in adult subjects with recurrent or refractory advanced cancers with aberration(s) in FGF/FGFR signaling. Treatment will consist of daily oral administration of Lenvatinib in 28-day cycles.

This exploratory, histology-independent study will enroll up to 39 subjects regardless of FGF/FGFR aberration or cancer type in order to test the hypothesis that subjects with advanced cancers harboring changes in FGF/FGFR-related genes will respond to the multikinase inhibitor lenvatinib at a higher rate than unselected cancer patients, regardless of the tumor histological subtype.

Lenvatinib is a multikinase inhibitor that inhibits FGFR1-4 as well as VEGFR1-3, RET, KIT and PDGFR-beta. It inhibits FGFR1 with an IC50 of 46 nmol/L, which is highly potent at a clinically relevant concentration.

Fibroblast growth factor (FGF) and FGF receptor (FGFR) pathway aberrations are common in malignancy, making this pathway a potentially appealing target for anti-cancer therapy. Clinical trial data suggest that targeting FGFR is indeed effective in cancer. However, the majority of such data come from trials in patient populations unselected for FGF/FGFR pathway abnormalities. The true response rates or clinical benefits for those whose cancers harbor FGF/FGFR abnormalities may be higher than observed in unselected patient populations.

Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling

A Multicenter, Histology-Independent Study of the Fibroblast Growth Factor Receptor (FGFR) Inhibitor Lenvatinib (E7080) in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling

Adverse events will be evaluated to determine:

* duration (start and end dates)
* severity (grade)
* seriousness
* relationship to study agent
* action taken (i.e., none, study agent modification, medical intervention)
* outcome (i.e., resolved without sequelae, resolved with sequelae, ongoing)

Eisai Co., Ltd.

Associate Clinical Professor

Endothelial Growth Factors

Lucitanib

Lucitanib is an oral multi kinase inhibitor designed to block the action of certain molecules called "angiogenic factors" that may cause tumors to grow. These factors are called vascular endothelial growth factor (VEGF), platelet derived growth factor receptor (PDGFR) and fibroblast growth factor (FGF). Lucitanib is experimental and not approved by the FDA for the treatment of cancer.

The purpose of this study is to look at the effects of lucitanib in cancer patients whose cancers harbor aberrations in FGFR, VEGFR, PDGFR or other markers predicted to be sensitive to lucitanib. This study will also look for biomarkers in samples of blood and tumor tissue to identify patients most likely to respond to lucitanib. Biomarkers are substances such as genetic material (DNA and RNA) and proteins found in blood and tumor tissue that might show if a cancer patient will respond or not respond to a drug.

Lucitanib is an oral multi kinase inhibitor designed to block the action of certain molecules called "angiogenic factors" that may cause tumors to grow. These factors are called vascular endothelial growth factor (called VEGF), platelet derived growth factor receptor (PDGFR) and fibroblast growth factor (called FGF). Lucitanib is experimental and not approved by the FDA for the treatment of cancer.

The purpose of this clinical trial is to study the following in cancer patients whose cancers harbor aberrations in FGFR, VEGFR, PDGFR, or other biomarkers predicted to be sensitive to lucitanib:

* To look at the effects of lucitanib on their disease at 10 mg once daily.
* To look for biomarkers in samples of blood and tumor tissue to identify patients most likely to respond to lucitanib.
* To look at the safety of lucitanib in these patients

This is a two-center, open-label, non-randomized Phase II study of lucitanib in adult subjects with advanced cancers. Treatment will consist of daily oral administration of 10mg of lucitanib in 28-day cycles.

All patients providing informed consent will be screened for eligibility. Baseline assessments will include vital signs, physical exam, blood hematology and chemistries, ECG, and ECHO. If not done within the prior 4 weeks, a PET/CT scan, MRI, and/or CT scan will be performed for radiological evaluation of disease.

Clinical evaluations include physical exam, vitals, ECG (obtained once every month throughout treatment); blood hematology and chemistries (obtained every two weeks for the first three months and then once every month throughout treatment); radiologic evaluations (PET/CT, CT and/or MRI, +/- bone imaging as clinically appropriate) will be performed every 8 weeks.

This study may last up to approximately 4 years or longer, depending on whether or not the study doctor feels that continuing lucitanib dosing is in the patient's best interest. Once a patient finishes study treatment with lucitanib, patients will need to complete an End of Study visit. Each of the study visits can last from approximately 2 to 8 hours.

Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations

Histology-Independent Study of the Multikinase Inhibitor Lucitanib (E3810) in Patients With Advanced Cancer and Fibroblast Growth Factor Receptor (FGFR), Vascular Endothelial Growth Factor Receptors (VEGFR), or Platelet Derived Growth Factor Receptor (PDGFR) Pathway Aberrations

Clinical Benefit will be defined as SD ≥ 6 cycles and PR/CR of any duration.

Toxicities will be described according to the NCI-CTCAE Version 4.3. Unacceptable toxicity is defined as any clinically significant Grade 3 or 4 toxicity including expected toxicities definitely, probably, or possibly related to the study medication that are not amenable to dose reduction

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Derazantinib and Atezolizumab in Patients With Urothelial Cancer	NCT04045613	Urothelial Carc...	Derazantinib 30... Derazantinib 20... Derazantinib 30... Derazantinib 20... Derazantinib 30... Derazantinib 30... Derazantinib 20...	18 Years -	Basilea Pharmaceutica
Phase I BLASST-3 Trial	NCT04972253	Bladder Transit... Bladder Cancer Fibroblast Grow...	Infigratinib	18 Years -	Dana-Farber Cancer Institute
Phase 1b Trial of BGJ398/BYL719 in Solid Tumors	NCT01928459	Advanced Solid ... Metastatic Soli...	BGJ398 BYL719	18 Years -	Novartis
Phase I BLASST-3 Trial	NCT04972253	Bladder Transit... Bladder Cancer Fibroblast Grow...	Infigratinib	18 Years -	Dana-Farber Cancer Institute
Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling	NCT02846766	Cancer	Lenvatinib	18 Years -	University of California, San Diego
Derazantinib and Atezolizumab in Patients With Urothelial Cancer	NCT04045613	Urothelial Carc...	Derazantinib 30... Derazantinib 20... Derazantinib 30... Derazantinib 20... Derazantinib 30... Derazantinib 30... Derazantinib 20...	18 Years -	Basilea Pharmaceutica
Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations	NCT02747797	Advanced Cancer	Lucitanib	18 Years -	University of California, San Diego

Spots Global Cancer Trial Database for fibroblast growth factor receptor